# Summit's ivonescimab misses the early squamous PFS bar in HARMONi-3; final readout still due in 2026

Canonical page: https://technooptimist.io/stories/summit-s-ivonescimab-misses-the-early-squamous-pfs-bar-in-harmoni-3-4b65fc4a
Date: 30 Apr 2026
About: [Summit Therapeutics](https://technooptimist.io/companies/summit-therapeutics.md) · [Ivonescimab](https://technooptimist.io/biotech/ivonescimab.md)
Original source: https://www.biospace.com/drug-development/summit-shares-descend-as-pd-1-vegf-asset-misses-early-survival-mark

Summit Therapeutics reported an interim progression-free survival analysis from the squamous lung cancer cohort of its Phase 3 HARMONi-3 trial, which compares ivonescimab plus chemotherapy with Keytruda. The result did not clear the statistical bar set for an earlier regulatory filing, and Summit's shares fell about 26%. An independent data monitoring committee recommended the trial continue unchanged.

## Key facts

- The interim analysis was meant to open talks with regulators ahead of a possible early filing; it did not meet the threshold for that.
- The independent data monitoring committee recommended the study continue as planned, and the trial remains double-blinded.
- Summit says it remains on track for the pre-planned final progression-free survival readout in the second half of 2026.
- Summit shares closed nearly 26% lower at $16.12 after the release.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.